Brokerages Set Oscar Health, Inc. (NYSE:OSCR) Price Target at $19.00

Oscar Health, Inc. (NYSE:OSCR) has been assigned an average recommendation of “Moderate Buy” from the nine analysts that are presently covering the firm, MarketBeat.com reports. Three investment analysts have rated the stock with a hold recommendation, five have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $19.75.

A number of research analysts have issued reports on the stock. Robert W. Baird assumed coverage on shares of Oscar Health in a research report on Thursday, May 30th. They set an “outperform” rating and a $28.00 price objective on the stock. Raymond James assumed coverage on shares of Oscar Health in a research report on Friday, March 22nd. They set an “outperform” rating and a $20.00 price objective on the stock. Bank of America reissued a “neutral” rating and set a $21.00 price objective (down from $25.00) on shares of Oscar Health in a research report on Thursday, May 30th. Wells Fargo & Company upped their target price on shares of Oscar Health from $24.00 to $27.00 and gave the stock an “overweight” rating in a research report on Wednesday, June 12th. Finally, The Goldman Sachs Group upped their target price on shares of Oscar Health from $16.00 to $21.00 and gave the stock a “neutral” rating in a research report on Thursday, May 9th.

Oscar Health Price Performance

Shares of NYSE OSCR opened at $16.59 on Wednesday. The company has a quick ratio of 1.10, a current ratio of 1.10 and a debt-to-equity ratio of 0.29. Oscar Health has a 52 week low of $4.72 and a 52 week high of $23.44. The firm’s fifty day moving average is $19.47 and its 200 day moving average is $15.54.

Oscar Health (NYSE:OSCR) last issued its earnings results on Tuesday, May 7th. The company reported $0.62 EPS for the quarter, topping the consensus estimate of $0.28 by $0.34. The company had revenue of $2.14 billion for the quarter, compared to the consensus estimate of $1.99 billion. Oscar Health had a negative net margin of 0.82% and a negative return on equity of 5.77%. The firm’s revenue for the quarter was up 45.8% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.18) earnings per share. As a group, analysts predict that Oscar Health will post -0.05 EPS for the current fiscal year.

Insider Buying and Selling

In related news, COO Steven Wolin sold 18,607 shares of the company’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $19.46, for a total value of $362,092.22. Following the transaction, the chief operating officer now owns 65,316 shares in the company, valued at approximately $1,271,049.36. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other Oscar Health news, COO Steven Wolin sold 18,607 shares of the company’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $19.46, for a total transaction of $362,092.22. Following the transaction, the chief operating officer now owns 65,316 shares in the company, valued at approximately $1,271,049.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Mario Schlosser sold 5,808 shares of the company’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $19.46, for a total transaction of $113,023.68. Following the transaction, the insider now owns 65,920 shares in the company, valued at approximately $1,282,803.20. The disclosure for this sale can be found here. Insiders have sold a total of 81,655 shares of company stock worth $1,589,006 in the last quarter. Corporate insiders own 25.11% of the company’s stock.

Institutional Investors Weigh In On Oscar Health

Hedge funds and other institutional investors have recently made changes to their positions in the business. Avalon Trust Co purchased a new stake in shares of Oscar Health during the 1st quarter valued at about $69,000. Prevail Innovative Wealth Advisors LLC purchased a new stake in Oscar Health in the 4th quarter worth approximately $92,000. Farallon Capital Management LLC purchased a new stake in Oscar Health in the 1st quarter worth approximately $164,000. Cornerstone Investment Partners LLC purchased a new stake in Oscar Health in the 1st quarter worth approximately $178,000. Finally, Handelsbanken Fonder AB purchased a new stake in Oscar Health in the 4th quarter worth approximately $110,000. Hedge funds and other institutional investors own 75.70% of the company’s stock.

About Oscar Health

Oscar Health, Inc operates as a health insurance in the United States. The company offers health plans in individual and small group markets, as well as +Oscar, a technology driven platform that help providers and payors directly enable their shift to value-based care. It also provides reinsurance products.